These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 24843712)

  • 1. Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus.
    Kadowaki T; Kondo K
    J Diabetes Investig; 2013 Nov; 4(6):576-84. PubMed ID: 24843712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.
    Kadowaki T; Kondo K
    Diabetes Obes Metab; 2014 May; 16(5):418-25. PubMed ID: 24205974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of teneligliptin add-on to insulin monotherapy in Japanese patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled trial with an open-label period.
    Kadowaki T; Kondo K; Sasaki N; Miyayama K; Yokota S; Terata R; Gouda M
    Expert Opin Pharmacother; 2017 Sep; 18(13):1291-1300. PubMed ID: 28741385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of teneligliptin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.
    Ji L; Ma J; Lu W; Liu J; Zeng J; Yang J; Li W; Zhang X; Xiao X; Takayanagi G; Wang Y
    J Diabetes Investig; 2021 Apr; 12(4):537-545. PubMed ID: 32810383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of teneligliptin added to metformin in Chinese patients with type 2 diabetes mellitus inadequately controlled with metformin: A phase 3, randomized, double-blind, placebo-controlled study.
    Ji L; Li L; Ma J; Li X; Li D; Meng B; Lu W; Sun J; Liu Y; Takayanagi G; Wang Y
    Endocrinol Diabetes Metab; 2021 Apr; 4(2):e00222. PubMed ID: 33855222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus.
    Kadowaki T; Kondo K
    Diabetes Obes Metab; 2013 Sep; 15(9):810-8. PubMed ID: 23464664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
    Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double-blind, placebo-controlled, parallel-group comparative study.
    Kadowaki T; Inagaki N; Kondo K; Nishimura K; Kaneko G; Maruyama N; Nakanishi N; Gouda M; Iijima H; Watanabe Y
    Diabetes Obes Metab; 2018 Feb; 20(2):453-457. PubMed ID: 28786530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of teneligliptin added to patients with type 2 diabetes inadequately controlled by oral triple combination therapy: A multicentre, randomized, double-blind, and placebo-controlled study.
    Lee M; Lee WJ; Kim JH; Lee BW
    Diabetes Obes Metab; 2022 Jun; 24(6):1105-1113. PubMed ID: 35229427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial.
    Eto T; Inoue S; Kadowaki T
    Diabetes Obes Metab; 2012 Nov; 14(11):1040-6. PubMed ID: 22776014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Teneligliptin in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Li X; Huang X; Bai C; Qin D; Cao S; Mei Q; Ye Y; Wu J
    Front Pharmacol; 2018; 9():449. PubMed ID: 29780322
    [No Abstract]   [Full Text] [Related]  

  • 12. Long-term safety and efficacy of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes.
    Kadowaki T; Inagaki N; Kondo K; Nishimura K; Kaneko G; Maruyama N; Nakanishi N; Watanabe Y; Gouda M; Iijima H
    Diabetes Obes Metab; 2018 Jan; 20(1):77-84. PubMed ID: 28608617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of teneligliptin added to ongoing metformin monotherapy in patients with type 2 diabetes: a randomized study with open label extension.
    Bryson A; Jennings PE; Deak L; Paveliu FS; Lawson M
    Expert Opin Pharmacother; 2016 Jul; 17(10):1309-16. PubMed ID: 27181910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sitagliptin added to treatment with ongoing pioglitazone for up to 52 weeks improves glycemic control in Japanese patients with type 2 diabetes.
    Kashiwagi A; Kadowaki T; Tajima N; Nonaka K; Taniguchi T; Nishii M; Ferreira JC; Amatruda JM
    J Diabetes Investig; 2011 Oct; 2(5):381-90. PubMed ID: 24843518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Teneligliptin in Indian Patients with Inadequately Controlled Type 2 Diabetes Mellitus: A Randomized, Double-blind Study.
    Agarwal P; Jindal C; Sapakal V
    Indian J Endocrinol Metab; 2018; 22(1):41-46. PubMed ID: 29535935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: 52-Week Results from a Prospective Observational Study.
    Kim HJ; Kim YS; Lee CB; Choi MG; Chang HJ; Kim SK; Yu JM; Kim TH; Lee JH; Ahn KJ; Min KW; Kyung EJ; Kim YK; Lee KW
    Diabetes Ther; 2021 Nov; 12(11):2907-2920. PubMed ID: 34536208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: A 12-Week Interim Report.
    Kim HJ; Kim YS; Lee CB; Choi MG; Chang HJ; Kim SK; Yu JM; Kim TH; Lee JH; Ahn KJ; Kim K; Lee KW
    Diabetes Ther; 2019 Aug; 10(4):1271-1282. PubMed ID: 31079357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.
    Einhorn D; Rendell M; Rosenzweig J; Egan JW; Mathisen AL; Schneider RL
    Clin Ther; 2000 Dec; 22(12):1395-409. PubMed ID: 11192132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.
    Reusch J; Stewart MW; Perkins CM; Cirkel DT; Ye J; Perry CR; Reinhardt RR; Bode BW
    Diabetes Obes Metab; 2014 Dec; 16(12):1257-64. PubMed ID: 25155146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
    Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
    Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.